CYTARABINE

Cytarabine

 

Composition: eachvial contains:  

active substance: cytarabine – 1000 mg, 100 mg.

Therapeutic indications

  • Lymphoblast and myeloblast leukemia.
  • Chronic myeloleukemia.
  • Erythroleukemia, lymphogranulomatosis.
  • Non-Hodgkin’s lymphoma.
  • Syndrome of bone marrow dysplasia.

The Cytarabine high-dose therapy is applied within the induction and consolidation programs under primary acute lymphoblast and myeloblast leukemia; under secondary leukemia developed either after the preceding cytostatic and/or beam therapy or as a result of the MDS transformation; under primarily resistant forms of acute leukemia; under resistant relapses of acute leukemia; under a blast crisis of chronic myeloleukemia; under resistant forms of highly malignant Hodgkin’s and non-Hodgkin’s lymphomas.

 

ATC code

L01BC01

Pharmaceutical form

lyophilized powder for solution for injection / solution for injection 20 mg/ml

Storage conditions

Store in protected from light place at temperature below 25°C.